Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jul 26, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.2K

BCR-ABL1淋巴细胞白血病的转录组类.

Jaeseung C Kim1,2,3, Michelle Chan-Seng-Yue1, Sabrina Ge1,3

  • 1Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Nature genetics
|June 19, 2023
PubMed
概括

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

Leukemia·2026
Same author

Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.

Nature·2026
Same author

Multi-platform reassessment of human mitochondrial DNA methylation reveals signals consistent with technical artifacts.

bioRxiv : the preprint server for biology·2026
Same author

Elevated mitochondrial protein import in acute myeloid leukemia increases reliance on mitochondrial protease LONP1.

The Journal of clinical investigation·2026
Same author

Mitochondrial RNA degradation regulates differentiation, stemness, and immune sensitivity in acute myeloid leukemia.

Nature communications·2026
Same author

Ex vivo expansion of hematopoietic stem and progenitor cells from human mobilized peripheral blood for gene therapy applications.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

在BCR-ABL1淋巴细胞白血病中,抗治疗性与B细胞成熟停止有关. 早期止会导致不良结果,而晚期止会导致更好的缓解率与氨酸激酶抑制剂 (TKIs).

科学领域:

  • 血液学 血液学 血液学
  • 分子生物学分子生物学
  • 在瘤学瘤学.

背景情况:

  • 在BCR-ABL1淋巴细胞白血病中,对氨酸激酶抑制剂 (TKIs) 的治疗异质性,特别是在没有激酶域突变的情况下,仍然不清楚.
  • 了解差异性TKI反应的分子驱动因素对于改善患者的治疗结果至关重要.

研究的目的:

  • 调查BCR-ABL1淋巴细胞白血病治疗异质性的分子基础.
  • 识别不同的分子亚型及其与临床结果和TKI疗效的相关性.

主要方法:

  • 对BCR-ABL1淋巴细胞白血病患者样本进行深度分子分析.
  • 转录基因亚型化以基于B细胞原始体分化阶段对白血病进行分类.
  • 基因组事件分析以确定与每个亚型相关的特定变化.

主要成果:

  • 确定了BCR-ABL1淋巴细胞白血病的三种转录组亚型,与不同的B细胞原始细胞成熟停止阶段相对应.
  • 较早的成熟停止与血统乱交,治疗阻断性和患者的不良结果相关.
  • 晚期成熟停止与血统忠诚度,持久缓解和改善患者结果相关.
  • 特定的基因组事件标志着每个成熟停止阶段,并且在白血病前干细胞中不存在,这表明转录基因表型的下游确定.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

182

相关实验视频

Last Updated: Jul 26, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.2K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.6K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

182

结论:

  • 在不同B细胞分化阶段的白血病转变决定了治疗反应和TKI疗效.
  • 转录基因亚型为理解和潜在预测BCR-ABL1淋巴细胞白血病TKI反应提供了一个框架.
  • 准差异化途径可能提供新的治疗策略.